CD5 and B-cell chronic lymphocytic leukemia: In the second part, we used an immortalized human leukemia T-cell line (Jurkat cells), which stably expresses the CD5 protein at high levels, and peripheral blood mononuclear cells (PBMC) from B-CLL patients to assess the ability of PNA to down-regulate the expression of CD5 as intended.